| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/04/2022 | — | Raymond James | Upgrades | Outperform → Strong Buy | |
| 03/07/2022 | 207.69% | Cowen & Co. | $28 → $14 | Maintains | Outperform |
| 02/22/2022 | 405.49% | Raymond James | $28 → $23 | Downgrades | Strong Buy → Outperform |
| 09/15/2020 | — | Jefferies | Initiates Coverage On | → Buy | |
| 09/10/2020 | 383.52% | Lake Street | → $22 | Initiates Coverage On | → Buy |
| 04/01/2020 | 229.67% | Cowen & Co. | → $15 | Initiates Coverage On | → Outperform |
Profound Medical Questions & Answers
The latest price target for Profound Medical (NASDAQ: PROF) was reported by Raymond James on November 4, 2022. The analyst firm set a price target for $0.00 expecting PROF to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Profound Medical (NASDAQ: PROF) was provided by Raymond James, and Profound Medical upgraded their strong buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on November 4, 2022 so you should expect the next rating to be made available sometime around November 4, 2023.
While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a upgraded with a price target of $0.00 to $0.00. The current price Profound Medical (PROF) is trading at is $4.55, which is out of the analyst's predicted range.